Monthly vs. quarterly shots: can a simple switch boost ovarian suppression in young breast cancer?

NCT ID NCT07610733

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial will enroll 100 young women (ages 18-45) with hormone receptor-positive breast cancer who are already on a 3-month GnRH injection for ovarian suppression. Half will switch to a monthly injection, while the other half stays on the 3-month schedule. The study aims to see if the switch leads to better control of estrogen levels at 3 months, which is important for managing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GnRH agonists (goserelin or leuprolide) plus endocrine therapy (aromatase inhibitor/tamoxifen ± CDK4/6 inhibitor)
What this could lead to
If successful, this could show that switching to a monthly GnRH injection provides better ovarian suppression, potentially improving treatment outcomes for young breast cancer patients.
What could go wrong
This is a small Phase 2 study (100 participants) and has not yet started recruiting. The primary endpoint is a hormone level, not a direct measure of cancer recurrence or survival, so benefits may not translate to better long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.